Crafting a genomics strategy early is key for successful oncology drug development
Discover three key considerations for crafting a successful genomic biomarker strategy in this article.
An historic shift towards treating cancer based on a tumor’s genetics rather than its site of origin is underway. Genomically-targeted drugs, properly developed, have an inherent advantage over drugs that are not. But the success of any one will depend on good strategic planning, done early. Read about three key considerations for crafting a successful genomic biomarker strategy.